Cronos Group Inc vs SPDR Kensho Final Frontiers ETF — how do they compare? Cronos Group Inc trades at $3.23 (market cap $1.20B), while SPDR Kensho Final Frontiers ETF trades at $102.84 (market cap $176.19M). The key difference: Cronos Group Inc is far larger — about 6.8× SPDR Kensho Final Frontiers ETF's market cap, and Cronos Group Inc is trading nearer its 52-week high, SPDR Kensho Final Frontiers ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Cronos Group Inc for 22 Days and SPDR Kensho Final Frontiers ETF for 8 Days on average.
| CRON | ROKT | |
|---|---|---|
Market Cap | $1.20B | $176.19M |
Volume | 450,387 | 34,479 |
Sector | Health | Sector/Thematic |
52-Week High | $3.55 | $136.68 |
52-Week Low | $2.30 | $72.93 |
Typical Hold Time | 22 Days | 8 Days |
Enterprise Value | $401.73M | — |
Signals from Pluang's Aura AI — not financial advice
CRON trades at $3.22, down 1.98% on the day, amid a bearish technical signal. The company reported mixed quarterly earnings but achieved record revenue and gross profit in Q2 2026, with net income turning positive. Recent investor day highlighted international expansion and cash flow focus. Valuation ratios show a P/E of 17.11 and P/S of 6.91, with strong net income margin of 39.08% projected for 2026.
Outlook is cautiously optimistic, driven by revenue growth and profitability improvements, but risks include cash flow volatility and competitive pressures. Analyst consensus is mixed with 60% hold rating. The stock's near-term performance hinges on execution of expansion plans and sustained earnings momentum.
No Aura AI signal available yet.
Trailing returns across standard periods
Latest headlines on both assets
Cronos Group, headquartered in Toronto, Canada cultivates and sells medicinal and recreational cannabis through its medicinal brand, Peace Naturals, and its two recreational brands, Cove and Spinach. Although it primarily operates in Canada, Cronos exports medical cannabis to Poland and Germany. In addition, it has entered joint ventures in Israel, Colombia, and Australia to drive further international cultivation and distribution growth. In the U.S. the company directly sells hemp-derived CBD and has an option to acquire 10.5% of U.S. multistate operator PharmaCann.
Read more on CRON →SPDR Kensho Final Frontiers ETF seeks exposure to companies supporting exploration of outer space and the deep sea. Its holdings include businesses involved in aerospace, defense, communications, research, and related technologies.
Read more on ROKT →